Displaying drugs 12576 - 12600 of 15140 in total
V24343
The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Investigational
Matched Description: … The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's …
AP1081
A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.
Investigational
Matched Description: … A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma …
TBC-3711
TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.
Investigational
Matched Description: … TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous …
Saredutant
Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigational
Matched Description: … Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic …
Telbermin
Telbermin has been used in trials studying the treatment of Foot Ulcer, Foot Ulcer, Diabetic, and Amyotrophic Lateral Sclerosis.
Investigational
Matched Description: … Telbermin has been used in trials studying the treatment of Foot Ulcer, Foot Ulcer, Diabetic, and Amyotrophic …
Lapaquistat
Lapaquistat is under investigation in clinical trial NCT00256178 (Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.).
Investigational
Matched Description: … Lapaquistat is under investigation in clinical trial NCT00256178 (Efficacy of Lapaquistat Acetate and …
Necuparanib
Necuparanib is under investigation in clinical trial NCT01621243 (M402 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer).
Investigational
Matched Description: … Necuparanib is under investigation in clinical trial NCT01621243 (M402 in Combination With Nab-paclitaxel and …
JNJ-17216498
JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.
Investigational
Matched Description: … JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment …
XL281
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and ... activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and …
Oxaprotiline
Oxaprotiline is a norepinephrine reuptake inhibitor of the tetracyclic antidepressant family that is related to maprotiline. This drug was never marketed. Oxaprotiline is a racemic mixture of the isomers levoprotiline and dextroprotiline. Levoprotiline is the R or levo isomer of oxaprotiline (CGP-12,103-A). Dextroprotiline is the S or dextro isomer of...
Experimental
Matched Description: … Oxaprotiline is a racemic mixture of the isomers levoprotiline and dextroprotiline. ... Both enantiomers have antidepressant effects but levoprotiline also is an antihistamine and dextroprotiline …
AG0301-COVID19
AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA...
Investigational
Matched Description: … AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. ... The gene transfer method increases the efficiency of gene expression and antibody production capability …
Mito-4509
Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.
Investigational
Matched Description: … It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic …
Toloxatone
Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) .
Experimental
Matched Description: … It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388]. …
Dipropyl-4-hydroxytryptamine
Dipropyl-4-hydroxytryptamine is the 4-hydroxyl analog of dipropyltryptamine (DPT). Dipropyl-4-hydroxytryptamine was first synthesized by Alexander Shulgin. This agent and its properties haven't been fully elucidated.
Experimental
Matched Description: … This agent and its properties haven't been fully elucidated. …
AZD-9977
AZD-9977 is under investigation in clinical trial NCT03843060 (A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers).
Investigational
Matched Description: … clinical trial NCT03843060 (A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and …
Aganepag isopropyl
Aganepag isopropyl is under investigation in clinical trial NCT01110499 (Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension).
Investigational
Matched Description: … Aganepag isopropyl is under investigation in clinical trial NCT01110499 (Safety and Efficacy of AGN-210961 …
Efmarodocokin alfa
Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
Investigational
Matched Description: … Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and …
CDX-6512
CDX-6512 is a modified, gastrointestinal-stable bacterial leucine decarboxylase. Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.[L46651, L46656]
Investigational
Matched Description: … Developed by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine …
ABT-751
ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.
Investigational
Matched Description: … ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell …
Dihydroxyacetone phosphate
Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
Investigational
Matched Description: … Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. …
Fx-1006A
Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
Investigational
Matched Description: … compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and …
Squaric acid dibutyl ester
Squaric acid dibutyl ester is under investigation in clinical trial NCT01971385 (Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis).
Investigational
Matched Description: … Squaric acid dibutyl ester is under investigation in clinical trial NCT01971385 (Safety and Efficacy …
LY-2624803
LY-2624803 is under investigation in clinical trial NCT01236105 (Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject).
Investigational
Matched Description: … LY-2624803 is under investigation in clinical trial NCT01236105 (Effect of Activated Charcoal and Time …
Technetium Tc-99m epratuzumab
Technetium Tc-99m epratuzumab is under investigation in clinical trial NCT00003337 (Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma).
Investigational
Matched Description: … under investigation in clinical trial NCT00003337 (Radiolabeled Monoclonal Antibody in the Detection and …
Brazikumab
Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).
Investigational
Matched Description: … Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study …
Displaying drugs 12576 - 12600 of 15140 in total